Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a open-label single dose escalation study of ensovibep in symptomatic COVID-19
2021-000365-33Phase 2Completed
- Sponsor
- Molecular Partners AG
- Start
- Mar 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ensovibep in coronavirus disease 2019 (COVID-19), sponsored by Molecular Partners AG. Primary endpoint: Changes in viral load and viral cultures. Started Mar 2021; status: completed.
02
Drugs
ensovibep
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-000365-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000365-33.